4016.SR
Middle East Pharmaceutical Industries Company
Healthcare · ·
$58.35
Data: 2026-05-28
✓ ETHICAL PASS
STRONG MOAT
MODERATE
Data Confidence: 71.4%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$550M
Total market value of the company
Rev Growth
+33.7%
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Middle East Pharmaceutical Industries Company
Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export.
Country: Saudi Arabia Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
N/A
Core business does not involve prohibited activities
Debt Ratio
0.0%
Debt must be below 33% of total assets
Cash Ratio
0.0%
Interest-bearing cash below 33% of assets
Receivables
0.0%
Receivables below 49% of assets
Revenue Purity
0.0%
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
Overall assessment combining ethics, valuation, and quality
Ethical Score
N/A
Valuation Score
71.5
Quality Score
52.5
Combined
45.6
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-9.8%
Historical annualised return based on price data
Days in State
2
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
N/A
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
23.3%
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28